While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

The popularity of weight loss drugs has caused a shortage in recent years, but how effective are they at helping with food ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides.

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

The common theme at the maker of Wegovy and at UnitedHealth may be investors' sudden awareness of cost-cutting pressure.

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

ORLANDO -- Fracture risk may be higher after bariatric surgery than after treatment with weight-loss drugs, propensity-score ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.